{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.38","value":"-23.7"},{"groupId":"OG001","spread":"27.27","value":"-26.7"},{"groupId":"OG002","spread":"26.33","value":"-28.0"},{"groupId":"OG003","spread":"25.99","value":"-28.1"},{"groupId":"OG004","spread":"26.98","value":"-29.5"},{"groupId":"OG005","spread":"26.84","value":"-29.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"521"},{"groupId":"OG001","value":"479"},{"groupId":"OG002","value":"442"},{"groupId":"OG003","value":"414"},{"groupId":"OG004","value":"388"},{"groupId":"OG005","value":"367"}],"units":"Participants"}],"description":"The patient's assessment of the patient's current level of pain on a 100 mm horizontal VAS was recorded. The extreme left end of the line was described as \"no pain\" and the extreme right end as \"unbearable pain\". Change from baseline was calculated for given periods, and a negative change indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"MEAN","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Change From Baseline in Scores for Patient's Level of Pain Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}